Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C) Meeting Abstract
| Authors: | Lee, H. J.; Abramson, J. S.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Eva, D. D.; Hess, B. T.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; Gandhi, M.; Mowat, R.; Shah, H.; Rossi, G.; Hahn, U. H.; Prince, H. M.; Ho, L.; Guo, W.; Yasenchak, C. A.; Straus, D. J. |
| Abstract Title: | Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 9399 |
| End Page: | 9401 |
| Language: | English |
| ACCESSION: | WOS:000893230302175 |
| DOI: | 10.1182/blood-2022-156576 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
